ECTRIMS 2016: Alemtuzumab Benefits Continue Six Years Post-Treatment
Executive Summary
The continuing benefits of Sanofi’s multiple sclerosis therapy Lemtrada six years after two short courses bolster the case for its use early in the course of the disease.